Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

This study aimed to investigate the therapeutic efficacy of vitamin D (VD) in SCI‐induced muscle atrophy and to elucidate the underlying molecular mechanisms.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

On Day 3 post‐injury, mice received daily oral gavage of either VD (150 IU/kg) or vehicle (coconut oil) for 25 days.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D Ameliorates Skeletal Muscle Atrophy After Spinal Cord Injury by Upregulating TIGAR and Enhancing Mitochondrial Function

Study design awaiting verification · Journal of Cachexia, Sarcopenia and Muscle · 2026

Original publication title

Vitamin D Ameliorates Skeletal Muscle Atrophy After Spinal Cord Injury by Upregulating TIGAR and Enhancing Mitochondrial Function

Ziyue Dong; Ning Li; Yudong Guo; Haowei Sun; Wenying Shi; Menghai Zhou; Xianming Tong; Zhiyuan Wang; Fangyuan Qian; Yijing Guo

© 2026 The Author(s). Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

VD mitigates skeletal muscle atrophy following SCI by restoring metabolic and mitochondrial homeostasis through the upregulation of TIGAR. Our findings establish a strong preclinical rationale for investigating VD supplementation as a therapeutic strategy to preserve muscle health in SCI patients.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Skeletal muscle atrophy following spinal cord injury (SCI) is a debilitating secondary complication with no effective treatment. This study aimed to investigate the therapeutic efficacy of vitamin D (VD) in SCI‐induced muscle atrophy and to elucidate the underlying molecular mechanisms.

Source: Background

Abstract: What methods does the paper describe?

SCI patients' serum VD levels were measured, and muscle mass was assessed using dual‐energy X‐ray examination. Adult male C57BL/6 mice underwent a complete T10 spinal cord transection or sham surgery. On Day 3 post‐injury, mice received daily oral gavage of either VD (150 IU/kg) or vehicle (coconut oil) for 25 days. Body weight and motor function were assessed, and muscle‐specific parameters including hindlimb circumference, muscle mass, fibre cross‐sectional area (CSA) and fibre type composition were evaluated. Quantitative proteomics, Western blotting, and transmission electron microscopy (TEM) were further employed to investigate the molecular mechanisms in the gastrocnemius muscle.

Source: Methods

Abstract: Results

Serum VD level showed a significant positive correlation with the muscle index (R 2 = 0.6495, p < 0.01). Compared to vehicle‐treated SCI mice, VD supplementation significantly attenuated body weight loss and promoted motor recovery (p < 0.05). VD treatment markedly preserved hindlimb muscle mass (p < 0.01) and prevented the reduction in the CSA of gastrocnemius (p < 0.01), extensor digitorum longus (p < 0.05) and soleus muscles (p < 0.05). Furthermore, VD alleviated the SCI‐induced pathological shift from oxidative (Type I/IIA) to glycolytic (Type IIB) muscle fibres.

Proteomic analysis revealed that VD restored cellular energy metabolism homeostasis. And it was related to the upregulation of the metabolic regulator TIGAR (p < 0.05). This was associated with a significant increase in mitochondrial number (p < 0.001) and an improvement in mitochondrial ultrastructure.

Source: Results

Abstract: Conclusion

VD mitigates skeletal muscle atrophy following SCI by restoring metabolic and mitochondrial homeostasis through the upregulation of TIGAR. Our findings establish a strong preclinical rationale for investigating VD supplementation as a therapeutic strategy to preserve muscle health in SCI patients.

Source: Conclusion
Authors’ abstract

ABSTRACT

Background

Skeletal muscle atrophy following spinal cord injury (SCI) is a debilitating secondary complication with no effective treatment. This study aimed to investigate the therapeutic efficacy of vitamin D (VD) in SCI‐induced muscle atrophy and to elucidate the underlying molecular mechanisms.

Methods

SCI patients' serum VD levels were measured, and muscle mass was assessed using dual‐energy X‐ray examination. Adult male C57BL/6 mice underwent a complete T10 spinal cord transection or sham surgery. On Day 3 post‐injury, mice received daily oral gavage of either VD (150 IU/kg) or vehicle (coconut oil) for 25 days. Body weight and motor function were assessed, and muscle‐specific parameters including hindlimb circumference, muscle mass, fibre cross‐sectional area (CSA) and fibre type composition were evaluated. Quantitative proteomics, Western blotting, and transmission electron microscopy (TEM) were further employed to investigate the molecular mechanisms in the gastrocnemius muscle.

Results

Serum VD level showed a significant positive correlation with the muscle index (R 2 = 0.6495, p < 0.01). Compared to vehicle‐treated SCI mice, VD supplementation significantly attenuated body weight loss and promoted motor recovery (p < 0.05). VD treatment markedly preserved hindlimb muscle mass (p < 0.01) and prevented the reduction in the CSA of gastrocnemius (p < 0.01), extensor digitorum longus (p < 0.05) and soleus muscles (p < 0.05). Furthermore, VD alleviated the SCI‐induced pathological shift from oxidative (Type I/IIA) to glycolytic (Type IIB) muscle fibres.

Proteomic analysis revealed that VD restored cellular energy metabolism homeostasis. And it was related to the upregulation of the metabolic regulator TIGAR (p < 0.05). This was associated with a significant increase in mitochondrial number (p < 0.001) and an improvement in mitochondrial ultrastructure.

Conclusion

VD mitigates skeletal muscle atrophy following SCI by restoring metabolic and mitochondrial homeostasis through the upregulation of TIGAR. Our findings establish a strong preclinical rationale for investigating VD supplementation as a therapeutic strategy to preserve muscle health in SCI patients.

Publication and source details

Original title: Vitamin D Ameliorates Skeletal Muscle Atrophy After Spinal Cord Injury by Upregulating TIGAR and Enhancing Mitochondrial Function

Ziyue Dong; Ning Li; Yudong Guo; Haowei Sun; Wenying Shi; Menghai Zhou; Xianming Tong; Zhiyuan Wang; Fangyuan Qian; Yijing Guo

Journal of Cachexia, Sarcopenia and Muscle · 2026

* Correspondence:
Fangyuan Qian (qfyseu@163.com)
Yijing Guo (guoyijingseu@126.com)
© 2026 The Author(s). Journal of Cachexia, Sarcopenia and Muscle published by Wiley Periodicals LLC.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Natural Science Foundation of Jiangsu Province10.13039/501100004608 BK20242099 Zhongda Hospital Affiliated to Southeast University, Jiangsu Province High‐Level Hospital Construction Funds GSP‐LCYJFH25 Healthy China Fund of the China Social Work Development Foundation HIGHER2022120

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-07T21:39:52+00:00

DOI: 10.1002/jcsm.70401 · PMC13633408